Obesity Clinical Trials: Beyond BMI

For decades, body mass index (BMI) has served as the primary measure in obesity research, yet growing evidence highlights its limitations as a standalone tool for diagnosis and patient assessment. As clinical guidance evolves and global experts refine how obesity is defined, the focus is shifting toward a more comprehensive understanding of disease burden and risk.

Join internationally recognized obesity specialists Dr. Scott Isaacs and Prof. Carel le Roux as they explore the role of biomarkers in advancing obesity clinical trials beyond BMI alone. Learn how incorporating metabolic, physiological, and disease-related markers can improve diagnostic accuracy, support precision medicine approaches, and strengthen efforts to prevent and treat obesity-related conditions.

The discussion will also examine emerging challenges and opportunities for sponsors as they adapt trial strategies to support the development of safe, effective therapies for people living with obesity.